Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"immunotoxins"”.
-
Immunotoxins in hematology
Contains fulltext : 19005.pdf (Publisher’s version ) (Open Access)
-
Development and Characterization of recombinant immunotoxins for cervical carcinoma
… for treating advanced stage cancers are high. Immunotoxins are fusion proteins that consist of an antibody that binds specifically to the cancer cell connected to a protein toxin capable of killing the cell. Immunotoxins have proven to be a promising alternative to current treatment for cancer. …
-
Ex vivo elimination of normal and malignant T cells from bone marrow grafts by ricin A-chain immunotoxins
Contains fulltext : mmubn000001_074176420.pdf (Publisher’s version ) (Open Access)
-
Next-Generation version of pseudomonas exotoxin a based immunotoxins with reduced immunogenicity for triple negative breast cancer (TNBC) treatment
… study, we successfully developed recombinant immunotoxins by fusing an anti- hliv22 and anti-trop2 single chain variable fragment (scFv) antibody to a truncated mutant of Pseudomonas Exotoxin A (ETA') and deimmunized version of (ETA') RG7787, herewith termed (dETA') introducing a cysteine in …
-
Development of recombinant immunotoxins targeting overexpressed cell surface biomarkers trophoblast cell-surface antigen 2 and mesothelin for cervical cancer treatment
… therapeutic approaches, such as recombinant immunotoxins, which may offer targeted treatment options with reduced side effects compared to traditional therapies. In this study, we focused on developing a target-specific next-generation recombinant immunotoxin (rIT) to improve treatment …
-
Herstellung und Charakterisierung von rekombinanten, ETA-basierten CD64-Immuntoxinen zur Bekämpfung von dysregulierten Makrophagen bei chronischen Hautentzündungen
… of chronic inflammations, confirms this. The immunotoxins of the first generation cannot be produced (however) in homogeneous quality and their biological and physicochemical characteristics cannot be optimized adequately. The goal of this dissertation work therefore was to produce recombinant …
-
Konstruktion und Charakterisierung von rekombinanten Immuntoxinen zur Therapie von metastasierendem Pankreaskarzinom
… the application of monoclonal antibodies, immunotoxins or bispecific antibodies, is a promising alternative for treatment of pancreatic carcinoma. Since overexpression of EGF receptor (EGFR) in pancreatic tumors correlates with advanced clinical staging, tumor size and decreased survival of …
-
Engineering targeted proteins for intracellular delivery of biotherapeutics
… delivery in a uniquely specific manner. Immunotoxins were designed based on the plant toxin gelonin and targeted towards the canonical cancer-specific antigens: epidermal growth factor receptor and carcinoembryonic antigen. Using quantitative internalization flow cytometry matched with …
-
In silico investigation of the mechanism of ricin-catalysed depurination reaction and design of novel ricin inhibitors
… therapeutic agent where applications such as immunotoxins to treat cancer, AIDS and other diseases are actively being pursued. However, the prime challenge in such applications is the non specific cytotoxicity of ricin, which cannot currently be treated due to the absence of an effective …
-
Immunotoxin Monotherapy and Combinatorial Therapy With Immune Checkpoint Inhibitors for Malignant Brain Tumors
… this need, we have developed two novel targeted immunotoxins (ITs), D2C7-(scdsFv)-PE38KDEL (D2C7-IT) and NZ-1-(scdsFv)-PE38KDEL (NZ-1-IT). D2C7-IT was developed by fusing the single-chain variable fragment (scFv) of the D2C7 monoclonal antibody (mAb) with domains II and III of Pseudomonas …
-
Construction of a recombinant immunotoxin
… recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology. In general, this involves fusion of a toxin gene with sequence encoding a variety of clinically relevant proteins or peptides. Using these techniques a recombinant immunotoxin has …
-
Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
… formats can be used to develop recombinant immunotoxins (rITs) using protein toxins as cell-killing moieties to achieve targeted destruction of cancer cells. Pseudomonas exotoxin A (ETA) is a potent enzyme that disrupts the function of eukaryotic elongation factor 2, causing inhibition of …
-
Herstellung und Charakterisierung rekombinanter Immunotoxine aus anti-PSMA single-chain Antikörperfragmenten zur Therapie des Prostatakarzinoms
… erfüllen. <br>Zur Konstruktion eines anti-PSMA-Immunotoxins wurde das scFv A5 rekombinant an eine verkürzte Form des Pseudomonas Exotoxin A (PE40) gekoppelt, dem die in der Natur vorkommende Zellbindungsdomäne Ia fehlt. Diese wurde durch A5 ersetzt, was zu einer Spezifität gegenüber …
-
Herstellung, Expression und Charakterisierung von rekombinanten Antikörpern und Immuntoxinen gegen Phoma lingam, Sclerotinia sclerotiorum und Verticillium dahliae
… of antibody fusion proteins, so-called immunotoxins, that were specific for the pathogens and that carried fusion proteins that were toxic to the fungal pathogens. Thus, a prerequisite was the generation of pathogen specific antibodies. Further, these antibodies should maintain their …
-
Entwicklung, Optimierung und Charakterisierung anti-CD64-basierter Immuntherapeutika
Immunotoxins (ITs) commonly are composed of modified antibodies that are linked to a toxin either chemically or through the generation of a fusion protein. The antibody directs the IT to specific target cells where it binds to surface molecules and is internalized, allowing the cytotoxic component …
-
Development of SNAP-tag-based fusion proteins targeting HIV-1 viral reservoirs
… human epidermal growth factor 2 (HER2) receptor. Immunotoxins (ITs) composed of an antibody fragment fused to apoptosis-inducing protein toxins targeting cellsurface antigens have been used for therapy of refractory leukaemia. The anti-CD22 recombinant IT Moxetumomab pasudotox based on Pseudomonas …